Literature DB >> 15043625

The NxStage System One.

William R Clark1, Joseph E Turk.   

Abstract

Given the results of recent randomized controlled trials as well as staffing and budget challenges that today face many institutions across North America, a novel therapeutic approach is likely necessary to enable improvements in clinical outcomes for renal failure patients. The NxStage System One was developed to address these challenges. The system is an innovative, flexible device that delivers hemodialysis, hemofiltration, and/or ultrafiltration therapies to patients with renal failure or fluid overload. The unique characteristics of this system include a highly automated system design with a drop-in cartridge to facilitate training and simple operation; portable size and independence from dedicated infrastructure to minimize practical barriers to where therapy may be administered; use of high-quality premixed treatment fluids to enable capture of the potential clinical benefits of fluid purity without the hassles of local water treatment; and wide operating ranges to allow clinician flexibility in patient therapy prescriptions. In both the chronic and acute care environments, the System One presents clinicians with a new platform for delivering patient therapy improvements within real-world constraints.

Entities:  

Mesh:

Year:  2004        PMID: 15043625     DOI: 10.1111/j.0894-0959.2004.17220.x

Source DB:  PubMed          Journal:  Semin Dial        ISSN: 0894-0959            Impact factor:   3.455


  9 in total

1.  Low cefepime concentrations during high blood and dialysate flow continuous venovenous hemodialysis.

Authors:  F Perry Wilson; Marcus A Bachhuber; Daniel Caroff; Rebecca Adler; Douglas Fish; Jeffrey Berns
Journal:  Antimicrob Agents Chemother       Date:  2012-01-30       Impact factor: 5.191

2.  Creatinine generation is reduced in patients requiring continuous venovenous hemodialysis and independently predicts mortality.

Authors:  Francis P Wilson; Jessica M Sheehan; Laura H Mariani; Jeffrey S Berns
Journal:  Nephrol Dial Transplant       Date:  2012-01-23       Impact factor: 5.992

Review 3.  Intensive home haemodialysis: benefits and barriers.

Authors:  Karthik K Tennankore; Christopher T Chan; Simon P Curran
Journal:  Nat Rev Nephrol       Date:  2012-07-24       Impact factor: 28.314

4.  Cost of Dialysis Therapy by Modality in Manitoba.

Authors:  Alain Beaudry; Thomas W Ferguson; Claudio Rigatto; Navdeep Tangri; Sandi Dumanski; Paul Komenda
Journal:  Clin J Am Soc Nephrol       Date:  2018-07-18       Impact factor: 8.237

Review 5.  How to overcome barriers and establish a successful home HD program.

Authors:  Bessie A Young; Christopher Chan; Christopher Blagg; Robert Lockridge; Thomas Golper; Fred Finkelstein; Rachel Shaffer; Rajnish Mehrotra
Journal:  Clin J Am Soc Nephrol       Date:  2012-10-04       Impact factor: 8.237

Review 6.  Water quality in conventional and home haemodialysis.

Authors:  Matthew J Damasiewicz; Kevan R Polkinghorne; Peter G Kerr
Journal:  Nat Rev Nephrol       Date:  2012-10-23       Impact factor: 28.314

7.  The accuracy of a continuous volumetric balancing system in pediatric continuous renal replacement therapy.

Authors:  Mark R Hanudel; Isidro B Salusky; Joshua J Zaritsky
Journal:  Int J Artif Organs       Date:  2014-04-04       Impact factor: 1.595

8.  Renal replacement therapy in austere environments.

Authors:  Christina M Yuan; Robert M Perkins
Journal:  Int J Nephrol       Date:  2011-04-26

9.  Protein-bound solute removal during extended multipass versus standard hemodialysis.

Authors:  Sunny Eloot; Wim Van Biesen; Mette Axelsen; Griet Glorieux; Robert Smith Pedersen; James Goya Heaf
Journal:  BMC Nephrol       Date:  2015-04-18       Impact factor: 2.388

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.